Aurobindo Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has announced that its trading window will be closed starting October 1, 2025, and will remain shut until 48 hours after the company declares its unaudited financial results for the second quarter ending September 30, 2025. During this period, designated persons including promoters, directors, key managerial personnel, employees, connected persons, and their immediate relatives are prohibited from trading in the company's shares. The company has not yet announced the date of the board meeting to approve the Q2 results, but it will be communicated later. This is a routine compliance measure under SEBI's insider trading regulations, typically observed ahead of earnings announcements.
No direct impact on the stock price or existing shareholders. This is a standard regulatory notice that signals the upcoming Q2 FY26 earnings announcement, which could be a key catalyst for the stock depending on the results.